Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9 Meeting Abstract
| Authors: | Sborov, D. W.; Pawlyn, C.; Ishida, T.; Huang, J. S. Y.; Benjamin, R.; Iida, S.; Popat, R.; Kuroda, J.; Pianko, M. J.; Ramakrishnan, A.; Schuster, S. R.; Dabak, V. S.; Lesokhin, A. M.; Conte, U.; Soltantabar, P.; Hong, F.; Vandendries, E.; Fonseca, R. |
| Abstract Title: | Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9 |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401749 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.7522 |
| Notes: | Meeting Abstract: 7522 -- Source: Wos |
